Company intelligence / Profile preview

MacroGenics

Rockville, Maryland, USAmacrogenics.com ↗

Ownership: Public · MGNX
Employees: ~240
Development stage: Commercial

Overview

MacroGenics has successfully advanced three novel therapeutics to approval:

MARGENZA® for HER2-positive metastatic breast cancer,
ZYNYZ® for certain cancers,
TZIELD® for delaying the onset of type 1 diabetes in at-risk individuals. The company maintains a robust portfolio of clinical and preclinical candidates focused on oncology and immunology. Its platforms have enabled multiple strategic partnerships with global pharmaceutical companies. Clinical results have demonstrated efficacy in targeted indications such as HER2+ cancers and early-stage type 1 diabetes

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: monoclonal antibodies (mAbs)antibody derivativesbispecific antibodies (DART molecules)antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

34 assets

margetuximab

Approved

33 more assets in the full pipeline.

Request access →

Partnerships

Multiple alliances with leading pharmaceutical companies globally; over $1 billion raised via non-dilutive partnership capital since IPO. Specific partners not named but described as major pharma/biotech firms.

Financials

Market cap: $252.3M
Total revenue: $32.8M
Enterprise value: $114.1M

Beyond the preview

Go deeper on MacroGenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MacroGenics.

Explore the full profile